Immunocore (NASDAQ:IMCR) Price Target Lowered to $50.00 at JPMorgan Chase & Co.

Immunocore (NASDAQ:IMCR) had its price target trimmed by JPMorgan Chase & Co. from $54.00 to $50.00 in a research report sent to investors on Monday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other brokerages also recently weighed in on IMCR. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Immunocore in a report on Wednesday, March 12th. Needham & Company LLC reissued a “buy” rating and set a $71.00 target price on shares of Immunocore in a research report on Thursday, April 10th. Mizuho decreased their price target on shares of Immunocore from $38.00 to $33.00 and set a “neutral” rating for the company in a research note on Monday, April 7th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $35.00 price objective on shares of Immunocore in a research note on Friday, March 7th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, Immunocore presently has an average rating of “Moderate Buy” and an average price target of $63.73.

Immunocore Stock Performance

Shares of Immunocore stock opened at $26.92 on Monday. The firm has a market capitalization of $1.35 billion, a P/E ratio of -28.34 and a beta of 0.75. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. The business’s fifty day simple moving average is $28.86 and its 200 day simple moving average is $30.46. Immunocore has a 12 month low of $23.15 and a 12 month high of $62.74.

Insider Activity at Immunocore

In other news, Director Bros. Advisors Lp Baker acquired 807,338 shares of Immunocore stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average price of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the purchase, the director now owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. The trade was a 60.40 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 9.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Immunocore

Several institutional investors and hedge funds have recently bought and sold shares of IMCR. GF Fund Management CO. LTD. bought a new position in shares of Immunocore in the fourth quarter worth $25,000. China Universal Asset Management Co. Ltd. increased its stake in Immunocore by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock worth $248,000 after acquiring an additional 960 shares during the last quarter. NEOS Investment Management LLC raised its holdings in shares of Immunocore by 10.9% in the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock valued at $330,000 after acquiring an additional 1,102 shares in the last quarter. Tema Etfs LLC bought a new stake in shares of Immunocore during the 4th quarter valued at about $330,000. Finally, Virtus ETF Advisers LLC grew its holdings in shares of Immunocore by 39.0% during the fourth quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company’s stock worth $340,000 after purchasing an additional 3,238 shares in the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.